Adrenomedullin (1-12), Human Mechanisms, Clinical Applicatio

Adrenomedullin (1-12), Human: Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Adrenomedullin (1-12), human, is a synthetic peptide corresponding to the N-terminal 12 amino acids of the full-length adrenomedullin (AM) protein, a member of the calcitonin gene-related peptide (CGRP) family. Originally isolated from human pheochromocytoma, adrenomedullin is a multifunctional peptide hormone involved in vasodilation, angiogenesis, and modulation of inflammatory responses (Kitamura et al., 1993, Biochem Biophys Res Commun). The truncated fragment, Adrenomedullin (1-12), retains significant biological activity, particularly in vascular and cardiovascular contexts, and has emerged as a valuable research tool for dissecting the structure-function relationships of the AM peptide and its receptor interactions (Martinez et al., 2002, Peptides). Mechanistically, Adrenomedullin (1-12) exerts its effects primarily through binding to the calcitonin receptor-like receptor (CLR) in complex with receptor activity-modifying proteins (RAMPs), leading to activation of adenylate cyclase and increased intracellular cAMP levels (Hay et al., 2018, Pharmacol Rev). This signaling cascade results in smooth muscle relaxation, endothelial barrier stabilization, and anti-inflammatory effects. The peptide’s unique N-terminal sequence is critical for receptor binding and downstream signaling, distinguishing its pharmacological profile from other AM fragments and related peptides. [Related: JNK-IN-8]

Clinical Value and Applications
Adrenomedullin (1-12), human, has garnered attention for its potential clinical value in cardiovascular, renal, and inflammatory diseases. Its potent vasodilatory properties make it a candidate for the management of hypertension, heart failure, and pulmonary arterial hypertension (PAH). In preclinical models, Adrenomedullin (1-12) has demonstrated efficacy in reducing systemic vascular resistance and improving cardiac output without eliciting significant tachycardia, a common limitation of other vasodilators (Nagaya et al., 2000, Circulation). [Related: nmn compound] Beyond cardiovascular applications, Adrenomedullin (1-12) has shown promise in modulating endothelial barrier function, thereby reducing vascular leakage in conditions such as sepsis and acute respiratory distress syndrome (ARDS) (Temmesfeld-Wollbrück et al., 2007, Crit Care Med). Its anti-inflammatory and cytoprotective effects also suggest potential utility in chronic kidney disease (CKD), where it may attenuate glomerular injury and preserve renal function (Kato et al., 2003, Kidney Int). Furthermore, Adrenomedullin (1-12) is increasingly utilized as a research tool to elucidate the pathophysiological roles of endogenous AM and to develop novel therapeutic strategies targeting the AM signaling axis. [Related: ITF2357 (Givinostat)]

Key Challenges and Pain Points Addressed
Current treatments for cardiovascular and inflammatory diseases often face limitations such as suboptimal efficacy, adverse side effects, and lack of tissue specificity. For example, conventional vasodilators may induce reflex tachycardia or hypotension, while anti-inflammatory agents can compromise immune function or cause organ toxicity (Ponikowski et al., 2016, Eur Heart J). Adrenomedullin (1-12) addresses several of these challenges:
- **Selective Vasodilation**: Unlike non-specific vasodilators, Adrenomedullin (1-12) preferentially targets vascular smooth muscle and endothelium, reducing the risk of systemic hypotension and reflex tachycardia.
- **Endothelial Barrier Protection**: The peptide enhances endothelial integrity, mitigating vascular leakage and tissue edema, which are critical in sepsis and ARDS.
- **Anti-inflammatory Effects**: Adrenomedullin (1-12) modulates cytokine production and leukocyte adhesion, offering a dual benefit in inflammatory and cardiovascular pathologies.
- **Renal Protection**: By improving renal hemodynamics and reducing glomerular injury, Adrenomedullin (1-12) may slow CKD progression without the nephrotoxic risks associated with some conventional therapies. These attributes position Adrenomedullin (1-12) as a promising candidate for addressing unmet needs in the management of complex, multifactorial diseases.

Literature Review
A growing body of literature supports the pharmacological and therapeutic potential of Adrenomedullin (1-12), human. Key studies include: 1. **Kitamura et al. (1993, Biochem Biophys Res Commun)**: The seminal study that identified and characterized adrenomedullin, highlighting its potent vasodilatory effects in vitro and in vivo.
2. **Martinez et al. (2002, Peptides)**: Demonstrated that Adrenomedullin (1-12) retains significant biological activity, including vasodilation and cAMP elevation, and elucidated its receptor binding properties.
3. **Nagaya et al. (2000, Circulation)**: Showed that administration of AM peptides, including truncated forms, improved hemodynamics in animal models of heart failure without causing significant tachycardia.
4. **Temmesfeld-Wollbrück et al. (2007, Crit Care Med)**: Provided evidence that AM peptides protect against vascular leakage and organ dysfunction in sepsis models, supporting their potential in critical care.
5. **Kato et al. (2003, Kidney Int)**: Reported that AM and its fragments ameliorate glomerular injury and preserve renal function in experimental nephropathy.
6. **Hay et al. (2018, Pharmacol Rev)**: Reviewed the molecular pharmacology of AM and its fragments, emphasizing the importance of RAMP interactions in mediating biological effects.
7. **Lamas et al. (2019, Front Physiol)**: Explored the role of AM peptides in endothelial function and inflammatory modulation, underscoring their relevance in vascular pathologies. Collectively, these studies provide a robust foundation for the continued investigation and therapeutic development of Adrenomedullin (1-12).

Experimental Data and Results
Experimental investigations of Adrenomedullin (1-12), human, have elucidated its pharmacodynamic and pharmacokinetic properties. In vitro studies demonstrate that Adrenomedullin (1-12) induces concentration-dependent relaxation of isolated vascular smooth muscle, with EC50 values comparable to full-length AM (Martinez et al., 2002, Peptides). The peptide also stimulates cAMP accumulation in endothelial and smooth muscle cells, confirming activation of the CLR/RAMP receptor complex. In vivo, administration of Adrenomedullin (1-12) in rodent models results in dose-dependent reductions in mean arterial pressure and systemic vascular resistance, without significant increases in heart rate (Nagaya et al., 2000, Circulation). In models of sepsis, the peptide reduces vascular leakage, improves organ perfusion, and attenuates inflammatory cytokine release (Temmesfeld-Wollbrück et al., 2007, Crit Care Med). Renal studies reveal that Adrenomedullin (1-12) enhances renal blood flow, reduces proteinuria, and mitigates glomerular injury in models of nephropathy (Kato et al., 2003, Kidney Int). These effects are attributed to both direct vasodilatory actions and modulation of inflammatory pathways. Pharmacokinetic analyses indicate that Adrenomedullin (1-12) is rapidly cleared from the circulation, necessitating continuous or repeated administration for sustained effects. However, its short half-life may also limit systemic side effects and facilitate precise titration in experimental settings.

Usage Guidelines and Best Practices
For research applications, Adrenomedullin (1-12), human, is typically supplied as a lyophilized powder and should be reconstituted in sterile, endotoxin-free water or buffer. The peptide is stable at -20°C and should be protected from repeated freeze-thaw cycles to preserve bioactivity. **In vitro studies**: Concentrations ranging from 1 nM to 1 μM are commonly employed, depending on cell type and experimental endpoint. It is recommended to include appropriate controls, such as vehicle and full-length AM, to delineate specific effects attributable to the (1-12) fragment. **In vivo studies**: Dosing regimens vary by species and disease model but generally involve intravenous or subcutaneous administration at doses of 0.1–10 μg/kg. Continuous infusion via osmotic minipumps may be used to maintain steady plasma levels. Researchers should monitor hemodynamic parameters, renal function, and inflammatory markers to assess efficacy and safety. **Storage and handling**: Reconstituted solutions should be aliquoted and stored at -80°C for long-term use. Avoid exposure to light and repeated freeze-thaw cycles. **Controls and validation**: It is essential to validate peptide purity and sequence by mass spectrometry or HPLC, especially for mechanistic studies. Use of receptor antagonists or gene-silencing approaches can help confirm specificity of observed effects.

Future Research Directions
Despite promising preclinical data, several questions remain regarding the optimal therapeutic use of Adrenomedullin (1-12), human. Future research should focus on: - **Pharmacokinetic Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 20 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11584406